

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Imaging			
Combined radioactive and fluorescent imaging agent that binds prostate-specific membrane antigen (PSMA; FOLH1; GCPII)	Mouse studies identified an ¹¹¹ indium (¹¹¹ In)-radiolabeled fluorescent compound that could help image prostate cancer. In mouse models of human prostate cancer, the compound specifically labeled PSMA-positive tumors. Next steps could include testing the compound in larger animal models of prostate cancer. <i>SciBX</i> 4(35); doi:10.1038/scibx.2011.1001 Published online Sept. 8, 2011	Patent applications filed; available for licensing	Banerjee, S.R. <i>et al. Angew. Chem. Int. Ed.</i> ; published online Aug. 22, 2011; doi:10.1002/anie.201102872 Contact: Martin G. Pomper, The Johns Hopkins University, Baltimore, Md. e-mail: mpomper@jhmi.edu